摘要
目的评价盐酸甲氯芬酯治疗急性缺血性脑卒中的临床疗效和安全性。方法198例经头颅CT或MRI确诊为急性缺血性脑卒中，且美国国立卫生院神经功能缺损评分（NIHSS）为8-22分的患者被随机分为两组：盐酸甲氯芬酯组103例，对照组95例。盐酸甲氯芬酯组在对照组治疗用药基础上加用盐酸甲氯芬酯0．25g（加入0．9％氯化钠溶液250mL中）静脉滴注，一日1次，14天为一个疗程。结果治疗后第3、7、14、28天。盐酸甲氯芬酯组患者NIHSS明显降低而生活能力状态（ADL）评分明显提高，与对照组相比差异显著（P〈0．05）；治疗后第3、7、14、28天盐酸甲氯芬酯组的总有效率显著高于对照组（P〈0．05）；两组不良事件的发生率无显著差异（P〉0．05）。结论盐酸甲氯芬酯能改善急性缺血性脑卒中患者的神经功能缺损，是一种治疗急性缺血性脑卒中安全而有效的药物。
Objective To evaluate the efficacy and safety of meclofenoxate hydrochloride in the treatment of acute cerebral infarction. Methods 198 patients with acute cerebral infarction（NIHSSs between 8 to 22） were randomly divided into two groups, the observer group（n=103） and the control group（n=95）. The observer group was administrated 0.9% sodium chloride injection 250mL containing meclofenoxate hydrochloride 0.25g for 14 days, whereas the control group was administrated routinely without meclofenoxate hydrochloride. Result The NIHSS and the ADL scales at day 3,7,14,28 showed that the observer group and the control group had significant differences （P〈0.05）. There was no significant difference in the adverse drug reaction between two groups（（P〈0.05）. Conclusion Meclofenoxate Hydrochloride is efficacious and safe in the treatment of acute cerebral infarction due to the improvement of neurological deficits and daily life activity of the patients.
出处
《世界临床药物》
CAS
2006年第8期461-464,共4页
World Clinical Drug
关键词
急性脑血管疾病
药物治疗
盐酸甲氯芬酯
cerebral infarction
drug therapy
NIH stroke scales
meclofenoxate hydrochloride
